Phase II study of Neoadjuvant Eribulin followed by FEC for operable triple-negative breast cancer
Phase of Trial: Phase II
Latest Information Update: 10 Jul 2018
Price : $35 *
At a glance
- Drugs Eribulin (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil
- Indications Breast cancer
- Focus Therapeutic Use
- 01 Jul 2018 Status changed from active, no longer recruiting to completed.
- 16 Nov 2015 Status changed from recruiting to active, no longer recruiting, as reported by University Hospital Medical Information Network - Japan record.
- 24 Jul 2014 New trial record